The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.
- Investigator
- Michael R Bubb
- Ages
- 18 Years - 75 Years
- Sexes
- All